Want to see IN:MANKIND full AI Analyst Report?

Mankind Pharma Ltd. (MANKIND) Price & Analysis

15 Followers

MANKIND Stock Chart & Stats

₹2505.40

₹44.40(1.77%)

At close: Jul 27 4:00 PM EDT

₹2505.40

₹44.40(1.77%)

Day’s Range― - ―

52-Week Range₹1,909.90 - ₹2,670.00

Previous CloseN/A

Volume185.79K

Average Volume (3M)10.08K

Market Cap

₹979.63B

Enterprise Value₹872.47K

Total Cash (Recent Filing)₹22.08B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)48.0

Beta0.59

Next Earnings

Nov 11, 2026

EPS Estimate

17.05

Next Dividend Ex-DateN/A

Dividend Yield0.04%

Share Statistics

EPS (TTM)49.49

Shares Outstanding412,995,970

10 Day Avg. Volume5,924

30 Day Avg. Volume10,081

Financial Highlights & Ratios

PEG Ratio-7.55

Price to Book (P/B)5.08

Price to Sales (P/S)5.80

P/FCF Ratio43.81

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹2,659.25

Price Target Upside6.14% Upside

Rating ConsensusHold

Number of Analyst Covering4

EPS Forecast (FY)57.48

Revenue Forecast (FY)₹160.48B

Bulls Say, Bears Say

Bulls Say

Consistent Revenue GrowthSustained revenue growth indicates continuing demand across Mankind Pharma’s branded prescription and consumer healthcare portfolio. Its broad therapy coverage and distribution reach can support further expansion while reducing reliance on any single product category.

Healthy Operating ProfitabilityHealthy profitability provides internal funding for product launches, sales infrastructure and manufacturing investment. Strong operating margins also indicate that the company’s branded formulations and consumer healthcare portfolio retain meaningful economic value.

Improved Leverage And Positive Free Cash FlowLower leverage improves financial flexibility and reduces balance-sheet pressure. Positive, growing free cash flow gives Mankind Pharma capacity to fund operations, expand its portfolio and manage obligations without relying excessively on external capital.

Bears Say

Margin CompressionThe decline in both net and EBIT margins suggests higher costs, weaker product mix or increased competitive pressure. If sustained, margin erosion could limit the benefit of revenue growth and reduce funds available for reinvestment.

Weak Operating Cash ConversionOperating cash flow materially below accounting earnings raises questions about working-capital absorption and earnings quality. Persistent weak conversion could constrain reinvestment, increase funding needs and make reported profit less dependable as a cash resource.

Lower Returns And Higher Historical DebtAlthough recent leverage improved, debt remains elevated versus the company’s earlier profile and reduces balance-sheet flexibility. Falling ROE also suggests incremental capital is producing weaker returns, which may limit efficient long-term growth.

Mankind Pharma Ltd. News

Mankind Pharma Realigns NCD Security Cover, Frees Pledge on Bharat Serums Stake

An update from Mankind Pharma Ltd. ( ($IN:MANKIND) ) is now available. Mankind Pharma has completed a realignment...

8d ago

Mankind Pharma Downgraded to Sell as Slowing Core Portfolios and Rising R&D/Acquisition Costs Undermine Premium Valuation

Nandan Kulkarni, an analyst from Bernstein, maintained the Sell rating on Mankind Pharma Ltd.. The associated price target...

25d ago

Mankind Pharma Board Clears Q1 FY27 Results and BSV Corporate Guarantee

Mankind Pharma Ltd. ( ($IN:MANKIND) ) has issued an update. Mankind Pharma’s board has approved the unaudited standalone...

26d ago

Mankind Pharma to Exit Non-Core Unit, Sets Up Dutch Arm for Niche R&D

Mankind Pharma Ltd. ( ($IN:MANKIND) ) has issued an announcement. Mankind Pharma’s board has approved the divestment of...

2M ago

Mankind Pharma Reshapes HR Leadership, Appoints Nilesh Kulkarni as Senior Management

Mankind Pharma Ltd. ( ($IN:MANKIND) ) has shared an announcement. Mankind Pharma Limited has undertaken an internal organisational...

3M ago

Mankind Pharma Overhauls HR Leadership, Names Nilesh Kulkarni Group HR Head

Mankind Pharma Ltd. ( ($IN:MANKIND) ) has issued an announcement. Mankind Pharma has restructured its human resources leadership,...

3M ago

Mankind Pharma Secures High CARE Ratings for ₹1,000 Crore Bank Facilities

An announcement from Mankind Pharma Ltd. ( ($IN:MANKIND) ) is now available. Mankind Pharma Limited has announced that...

4M ago

Mankind Pharma Publishes Q3 and Nine-Month FY26 Earnings Call Transcript

The latest update is out from Mankind Pharma Ltd. ( ($IN:MANKIND) ). Mankind Pharma Limited has released the...

7M ago

Mankind Pharma Challenges GST Order on Subsidiary Merger

Mankind Pharma Ltd. ( ($IN:MANKIND) ) just unveiled an announcement. Mankind Pharma Ltd. has announced that it received...

9M ago

Mankind Pharma Reports Strong Financial Performance for Q2 and H1 2025

The latest update is out from Mankind Pharma Ltd. ( ($IN:MANKIND) ). Mankind Pharma Ltd. announced its unaudited...

10M ago

MANKIND FAQ

What was Mankind Pharma Ltd.’s price range in the past 12 months?

Mankind Pharma Ltd. lowest stock price was ₹1909.90 and its highest was ₹2670.00 in the past 12 months.

What is Mankind Pharma Ltd.’s market cap?

Mankind Pharma Ltd.’s market cap is ₹979.63B.

When is Mankind Pharma Ltd.’s upcoming earnings report date?

Mankind Pharma Ltd.’s upcoming earnings report date is Nov 11, 2026 which is in 78 days.

How were Mankind Pharma Ltd.’s earnings last quarter?

Mankind Pharma Ltd. released its earnings results on Jul 30, 2026. The company reported ₹13.8 earnings per share for the quarter, beating the consensus estimate of ₹13.306 by ₹0.494.

Is Mankind Pharma Ltd. overvalued?

According to Wall Street analysts Mankind Pharma Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Mankind Pharma Ltd. pay dividends?

Mankind Pharma Ltd. pays a Notavailable dividend of ₹1 which represents an annual dividend yield of 0.04%. See more information on Mankind Pharma Ltd. dividends here

What is Mankind Pharma Ltd.’s EPS estimate?

Mankind Pharma Ltd.’s EPS estimate is 17.05.

How many shares outstanding does Mankind Pharma Ltd. have?

Mankind Pharma Ltd. has 412,995,970 shares outstanding.

What happened to Mankind Pharma Ltd.’s price movement after its last earnings report?

Mankind Pharma Ltd. reported an EPS of ₹13.8 in its last earnings report, beating expectations of ₹13.306. Following the earnings report the stock price went down -0.602%.

Which hedge fund is a major shareholder of Mankind Pharma Ltd.?

Currently, no hedge funds are holding shares in IN:MANKIND

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Mankind Pharma Ltd.

Mankind Pharma Limited specializes in the development, manufacturing, and marketing of a broad range of pharmaceutical medications and consumer health goods. Operating predominantly in India, the company also caters to international markets. Its pharmaceutical division focuses on both acute and chronic therapeutic areas, encompassing a wide spectrum of medical conditions such as infectious diseases, cardiovascular ailments, gastrointestinal disorders, diabetes, dermatology, pain management, neuro/CNS issues, nutritional support (vitamins/minerals), and respiratory problems. Complementing its pharmaceutical portfolio, the consumer healthcare segment offers diverse products, including condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. Key brands under its umbrella include Manforce, Prega News, Unwanted-72, Gas-O-Fas, Health OK, and AcneStar. Furthermore, the company's business activities are diversified, extending to the trading and export of pharmaceutical and healthcare products, as well as the manufacturing of various goods such as packaging materials, ayurvedic products, bulk drugs, and general consumer items. Mankind Pharma also holds interests in real estate, leasing, hospitality, and IT services. Established in 1986, Mankind Pharma Limited maintains its headquarters in New Delhi, India.

Mankind Pharma Ltd. (MANKIND) Earnings & Revenues

Historic Earnings Reports

MANKIND Stock 12 Month Forecast

Average Price Target

₹2,659.25

▲(6.14% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2000":"₹2,000","3221":"₹3,221","2305.25":"₹2,305.3","2610.5":"₹2,610.5","2915.75":"₹2,915.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3220,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹3.22K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2659.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹2.66K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2057,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹2.06K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2000,2305.25,2610.5,2915.75,3221],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2469.9,2527.6,2585.3,2643,2700.7000000000003,2758.4,2816.1,2873.8,2931.5,2989.2,3046.9,3104.6,3162.3,{"y":3220,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2469.9,2484.4653846153847,2499.0307692307692,2513.596153846154,2528.1615384615384,2542.726923076923,2557.2923076923075,2571.8576923076926,2586.423076923077,2600.9884615384617,2615.5538461538463,2630.119230769231,2644.6846153846154,{"y":2659.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2469.9,2438.138461538462,2406.376923076923,2374.6153846153848,2342.853846153846,2311.0923076923077,2279.3307692307694,2247.5692307692307,2215.8076923076924,2184.046153846154,2152.2846153846153,2120.523076923077,2088.7615384615383,{"y":2057,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2561.29,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2518.95,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2438.65,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2382.35,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2229.9,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2163.1,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2067.1,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2244.95,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2001.15,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2246.55,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2320.35,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2490.2,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2469.9,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >